Senior Correspondent, London
Ben's Feed
Mar 11, 2014
Mar 11, 2014

Ranbaxy scrambles for ingredients to make generic Nexium

MUMBAI/LONDON (Reuters) – Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc’s heartburn drug Nexium, a source said, to ensure the pills can be sold in the United States.

The United States banned shipments from one of Ranbaxy’s plants in India following an inspection that found poor manufacturing practices, effectively barring India’s top drugmaker by revenue from selling drugs in the United States from its India plants.

Mar 11, 2014
Mar 10, 2014

Proteus picks UK for ‘smart pill’ production and testing

LONDON (Reuters) – A U.S. biotech company pioneering tablets containing edible embedded microchips that can tell if patients have taken their medication is to establish its first international manufacturing site in Britain.

Privately held Proteus Digital Health, which is working with drugmakers including Novartis and Otsuka, said on Monday the new site would employ some 200 skilled staff and serve as a hub for the emerging digital medicine industry.

Mar 5, 2014
Mar 4, 2014
Mar 4, 2014
Mar 3, 2014

India’s Lupin seeks biosimilar, lung drug partners

MUMBAI (Reuters) – Indian drugmaker Lupin Ltd is seeking new partnership agreements as it moves into the promising fields of inhaled lung drugs and copies of biotechnology drugs, its managing director said.

The United States and Japan were the most interesting regions for so-called “biosimilar” developments by Lupin and the company is actively seeking partners with the right drug development expertise, Nilesh Gupta told Reuters in an interview.

Mar 3, 2014

Lupin seeks biosimilar, lung drug partners

MUMBAI (Reuters) – Indian drugmaker Lupin Ltd (LUPN.NS: Quote, Profile, Research) is seeking new partnership agreements as it moves into the promising fields of inhaled lung drugs and copies of biotechnology drugs, its managing director said.

The United States and Japan were the most interesting regions for so-called “biosimilar” developments by Lupin and the company is actively seeking partners with the right drug development expertise, Nilesh Gupta told Reuters in an interview.

Feb 13, 2014

Nestle hints at more deals after deeper healthcare dive

LONDON (Reuters) – Swiss food giant Nestle’s deeper dive into healthcare by taking over the dermatology joint venture it had with L’Oreal suggests further deals in the space are likely.

The move underscores Nestle’s determination to move beyond relatively stagnant traditional food markets into “wellness”, where growth prospects and profit margins are more enticing.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben